“…In the pursuit of the ideal biomarker(s), novel technologies, the maturity of which is steadily increasing, offer hope. For example, single-cell RNA sequencing [37,38] and profiling of T-cell receptors [36,58,59] used alone or in combination appear promising but, alas, unvalidated as prognostic, diagnostic, or mechanistic proxies of T1D risk, onset, or progression. In alignment with the central role of T cells in T1D immunopathogenesis, recent studies have found distinct T-cell repertoire profiles [60,61].…”